Business Insider

Recce Pharmaceuticals Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2

SYDNEY, Australia, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of synthetic anti-infectives, today announced results of RECCE ® ...
Business Insider

Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds

Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® ...
Hosted on MSN

Recce Pharmaceuticals secures A$85 million R&D tax incentive for global anti-infective programs

Recce Pharmaceuticals Ltd. ( (AU:RCE)) has shared an update. Recce Pharmaceuticals has been awarded an Advanced Overseas Finding for up to A$85 million by the Australian Government, which extends the ...
WGN-TV

Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections

Phase 1/2 trial of RECCE ® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical Research Study will assess the ...